These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26054088)

  • 1. Brentuximab vedotin (replased/refractory Hodgkin lymphoma and CD30 positive non-Hodgkin lymphoma.
    Kitahara H
    Gan To Kagaku Ryoho; 2015 May; 42(5):550-2. PubMed ID: 26054088
    [No Abstract]   [Full Text] [Related]  

  • 2. A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma.
    Oak E; Bartlett NL
    Expert Opin Drug Saf; 2016 Jun; 15(6):875-82. PubMed ID: 27139729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin.
    Deng C; Pan B; O'Connor OA
    Clin Cancer Res; 2013 Jan; 19(1):22-7. PubMed ID: 23155186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brentuximab vedotin as single agent in refractory or relapsed CD30-positive Hodgkin lymphoma: the French Name Patient Program experience in 241 patients.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):4-5. PubMed ID: 25768991
    [No Abstract]   [Full Text] [Related]  

  • 5. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Brentuximab vedotin: new treatment for CD30+ lymphomas].
    Terriou L; Bonnet S; Debarri H; Demarquette H; Morschhauser F
    Bull Cancer; 2013; 100(7-8):775-9. PubMed ID: 23831822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate.
    Newland AM; Li JX; Wasco LE; Aziz MT; Lowe DK
    Pharmacotherapy; 2013 Jan; 33(1):93-104. PubMed ID: 23307550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.
    Chen R; Chen B
    Drug Des Devel Ther; 2015; 9():1729-33. PubMed ID: 25848209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
    Gualberto A
    Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.
    Makita S; Maeshima AM; Taniguchi H; Kitahara H; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Kobayashi Y; Tobinai K
    Int J Hematol; 2016 Sep; 104(3):396-9. PubMed ID: 27169615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brentuximab vedotin for the treatment of CD30+ lymphomas.
    Foyil KV; Bartlett NL
    Immunotherapy; 2011 Apr; 3(4):475-85. PubMed ID: 21463188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hodgkin lymphoma].
    Nagai H
    Nihon Rinsho; 2014 Jun; 72(6):1099-103. PubMed ID: 25016811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper.
    Zinzani PL; Corradini P; Gianni AM; Federico M; Santoro A; Vitolo U; Barosi G; Tura S
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):507-13. PubMed ID: 26195435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
    Ansell SM
    Expert Opin Investig Drugs; 2011 Jan; 20(1):99-105. PubMed ID: 21121873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma.
    O'Sullivan CC; Ozdemirli M; Bazylewicz M; Cheson BD
    Clin Adv Hematol Oncol; 2013 Jun; 11(6):382-5. PubMed ID: 24472809
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies.
    Fabbri A; Cencini E; Gozzetti A; Schiattone L; Bocchia M
    Anticancer Agents Med Chem; 2017; 17(7):886-895. PubMed ID: 27592544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.
    de Claro RA; McGinn K; Kwitkowski V; Bullock J; Khandelwal A; Habtemariam B; Ouyang Y; Saber H; Lee K; Koti K; Rothmann M; Shapiro M; Borrego F; Clouse K; Chen XH; Brown J; Akinsanya L; Kane R; Kaminskas E; Farrell A; Pazdur R
    Clin Cancer Res; 2012 Nov; 18(21):5845-9. PubMed ID: 22962441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
    N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD30-targeted antibody therapy.
    Younes A
    Curr Opin Oncol; 2011 Nov; 23(6):587-93. PubMed ID: 21986847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of CD30 as a biomarker to predict response to brentuximab vedotin.
    Xu ML; Acevedo-Gadea C; Seropian S; Katz SG
    Histopathology; 2016 Jul; 69(1):155-8. PubMed ID: 26648051
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.